Valuation: GSK plc

Market Cap 76.13B 102B 88.54B 83.79B 142B 9,735B 143B 998B 386B 4,948B 382B 373B 15,838B P/E 2026 *
14.6x
P/E 2027 * 12.1x
Enterprise Value 96.81B 129B 113B 107B 181B 12,380B 182B 1,269B 491B 6,291B 486B 475B 20,141B EV / Sales 2026 *
2.85x
EV / Sales 2027 * 2.65x
Free-Float
92.75%
Yield 2026 *
3.66%
Yield 2027 * 3.94%
1 day-2.80%
1 week+3.15%
Current month-1.20%
1 month-2.94%
3 months-2.02%
6 months-4.64%
Current year+1.23%
1 week 49.56
Extreme 49.555
51.08
1 month 47.85
Extreme 47.85
52.94
Current year 47.62
Extreme 47.62
61.7
1 year 39.29
Extreme 39.29
61.7
3 years 31.72
Extreme 31.715
61.7
5 years 28.46
Extreme 28.465
61.7
10 years 28.46
Extreme 28.465
61.7
Manager TitleAgeSince
Chief Executive Officer 52 01/01/2026
Director of Finance/CFO 64 01/05/2023
Compliance Officer - 01/08/2018
Director TitleAgeSince
Director/Board Member 52 06/05/2026
Director/Board Member 64 01/01/2018
Chairman 67 01/09/2019
Change 5-day change 1-year change 3-year change Capi.($)
-2.75%+3.15% - - 102B
-0.53%+2.91%+50.49%+100.98% 1,027B
-0.58%+1.20%+54.33%+65.43% 651B
+0.02%+2.78%+19.04%+71.66% 467B
-1.19%+3.81%+36.63%+38.52% 350B
-0.62%+3.02%+19.36%+25.43% 268B
-0.01%+6.29%+10.63%+16.00% 257B
+0.74%+1.36%+38.67%+45.35% 205B
+0.79%+1.63%-28.42%-56.80% 190B
-0.33%+4.75%+32.50%+99.09% 187B
Average -0.49%+2.49%+25.92%+45.07% 400.23B
Weighted average by Cap. -0.46%+2.62%+34.84%+61.42%

Financials

2026 *2027 *
Net sales 33.93B 45.31B 39.46B 37.35B 63.39B 4,339B 63.71B 445B 172B 2,205B 170B 166B 7,059B 35.5B 47.4B 41.29B 39.08B 66.33B 4,540B 66.65B 465B 180B 2,307B 178B 174B 7,386B
Net income 5.35B 7.14B 6.22B 5.89B 9.99B 684B 10.04B 70.11B 27.11B 348B 26.82B 26.23B 1,113B 6.28B 8.39B 7.31B 6.92B 11.74B 804B 11.8B 82.38B 31.85B 408B 31.52B 30.82B 1,307B
Net Debt 20.68B 27.61B 24.05B 22.76B 38.64B 2,644B 38.83B 271B 105B 1,344B 104B 101B 4,302B 17.97B 23.99B 20.9B 19.78B 33.57B 2,298B 33.73B 236B 91.08B 1,168B 90.12B 88.12B 3,738B
Logo GSK plc
GSK plc is the world's No. 2 pharmaceutical group. Net sales break down by family of products as follows: - pharmaceutical products (41.3%): intended mainly for HIV infection (57% of net sales), immune system disorders and respiratory diseases (28.3%), and cancer (14.7%); - OTC and parapharmaceutical medicine (30.7%); - vaccines (28%). Net sales are distributed geographically as follows: the United Kingdom (2.1%), Europe (21%), the United States (51.6%), and other (25.3%).
Employees
66,841
Date Price Change Volume
18/09/26 $49.62 -2.82% 742,460
17/09/26 $51.06 +1.53% 3,075,204
16/09/26 $50.29 +0.56% 2,844,569
15/09/26 $50.01 -0.08% 2,739,771
14/09/26 $50.05 +3.99% 3,004,070
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
19.00GBP
Average target price
21.71GBP
Spread / Average Target
+14.26%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!